Medical device titan Medtronic completes enrollment in its IN.PACT SFA II trial evaluating its IN.PACT Admiral drug-eluting balloon in treatment of peripheral artery disease.

MASSDEVICE ON CALL — Minneapolis-based medical device company Medtronic (NYSE:MDT) announced closed enrollment in the U.S. arm of a study evaluating its IN.PACT Admiral drug-eluting balloon.

The multi-center study enrolled 181 patients with peripheral artery disease at more than 40 U.S. clinics, randomizing them to either receive treatment with the IN.PACT Admiral or a traditional, non-coated angioplasty balloon.